Baroda BNP Paribas Small Cap Fund
The Scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity related securities of small cap companies.
Growthvine rating: 1/5 — ranked #33 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹13.73 (as of 2026-10-01) |
|---|
| AUM | ₹1,309 Cr |
|---|
| Expense ratio | 1.85% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Himanshu Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −25.37% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 83.4% of NIFTY Smallcap 250's upside and 81.8% of its downside.
Market cap allocation
| Large cap | 5.8% |
|---|
| Mid cap | 17.2% |
|---|
| Small cap | 77.0% |
|---|
Concentration
| Top 5 holdings | 16.7% |
|---|
| Top 10 holdings | 29.4% |
|---|
| Total holdings | 61 |
|---|
| Index overlap | 19.3% |
|---|
| Active share | 80.7% |
|---|
Top holdings
- Karur Vysya Bank Ltd. — 3.7%
- Navin Fluorine International Limited — 3.7%
- Multi Commodity Exchange of India Ltd — 3.4%
- Laurus Labs Limited — 3.0%
- Ujjivan Small Finance Bank Limited — 2.8%
- Bharat Heavy Electricals Ltd. — 2.7%
- Radico Khaitan Ltd. — 2.7%
- Delhivery Limited — 2.5%
- Dr. Lal Pathlabs Limited — 2.4%
- Emcure Pharmaceuticals Limited — 2.4%
Top sectors
- Banking & Financial — 14.6%
- Pharma & Biotech — 11.1%
- Finance & Investments — 8.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 6.7% | Q3 | #23 of 34 |
| 2025 | −6.6% | Q3 | #23 of 30 |
| 2024 | 24.4% | Q3 | #17 of 28 |